anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

128,761-128,820 of 319,975

filter-aware
152
The slide uses a 'villain_critique' structure to undermine the company's core value proposition by citing internal dissent.Berkeley Lights (BLI) · Scorpion Capital
Research note Short seller 1 hit
153
The slide uses direct quotes from former employees to validate the thesis that the product is difficult to use.Berkeley Lights (BLI) · Scorpion Capital
Research note Short seller 1 hit
154
The slide uses direct quotes to validate the claim of high operational burden.Berkeley Lights (BLI) · Scorpion Capital
Research note Short seller 1 hit
155
Uses direct quotes from former employees to build a case against the company's value proposition.Berkeley Lights (BLI) · Scorpion Capital
Research note Short seller 1 hit
156
The slide uses expert testimony to frame Abcellera as a disruptive competitor to BLI.Berkeley Lights (BLI) · Scorpion Capital
Research note Short seller 1 hit
157
Includes direct quotes from former BLI scientists as evidence of competitive displacement.Berkeley Lights (BLI) · Scorpion Capital
Research note Short seller 1 hit
158
Uses testimonial-style quotes to build a case against the subject company (BLI).Berkeley Lights (BLI) · Scorpion Capital
Research note Short seller 1 hit
01
Slide 1
This is a formal legal/regulatory document cover letter/introductory page.Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller 1 hit
02
The slide uses a comparative historical analogy (Seldane) to frame the current safety concerns as a 'tragedy in the making'.Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller Beat · ComplicationLoop · Pattern Hunter1 hit
03
This slide appears to be part of a Citizen Petition or regulatory filing challenging the safety profile of a drug.Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller Beat · ComplicationLoop · Pattern Hunter1 hit
04
This appears to be a page from a regulatory petition or legal filing challenging the approval of a drug.Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller Beat · ComplicationLoop · Pattern Hunter1 hit
05
This is a page from a Citizen Petition document.Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller Beat · EvidenceLoop · Cost Of Inaction1 hit
06
This is a text-heavy regulatory filing page. It uses anecdotal evidence from prescriber interviews and social media to argue that current warnings are insufficient.Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller Beat · EvidenceLoop · Cost Of Inaction1 hit
07
The slide serves as a foundational disclosure for a regulatory filing, establishing the credibility and scope of the petitioner's investigative work.Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller Beat · Executive Summary1 hit
08
This appears to be a page from a legal or regulatory petition (Citizen Petition) detailing allegations against a drug product.Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller Beat · Appendix Disclosure1 hit
09
This is a standard legal/regulatory filing signature page.Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller Beat · Appendix Disclosure1 hit
10
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Kir Kahlon
Regulatory filing Short seller 1 hit
01
Slide 1
The slide uses highly aggressive, inflammatory language characteristic of activist short-seller reports.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller 1 hit
02
Ginkgo Bioworks (DNA)Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller 1 hit
03
The slide uses aggressive, accusatory language typical of short-seller activist decks.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller 1 hit
04
Ginkgo Bioworks (DNA)Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller 1 hit
05
Ginkgo Bioworks (DNA)Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller 1 hit
06
The slide uses aggressive, critical language typical of an activist short report.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller 1 hit
07
The slide uses aggressive, accusatory language to frame the company as a 'colossal fraud'.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
08
Includes a link to the China Hustle documentary trailer and a historical stock chart of Sino-Forest (TRE.TO) showing its collapse.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
09
The slide uses a combination of a table from a SPAC prospectus and screenshots of LinkedIn and corporate registry filings to build a case of a 'China Hustle-type scam'.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
10
Uses investigative field research to challenge the legitimacy of revenue sources.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
11
Uses the 'iceberg' metaphor to suggest deeper fraud. Includes a screenshot of a press release and a website as evidence.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
12
The slide uses red circles and arrows to highlight specific data points in the SEC filing to support the narrative of undisclosed related-party transactions.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
13
The slide uses a red box to highlight Ginkgo Bioworks as the most expensive company in the dataset.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
14
The slide uses a table of current shareholders to highlight the 'smart money' concentration.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
15
Uses specific examples of financial fraud and regulatory trouble to counter the 'halo effect' of Tiger Cub investment.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
16
The slide uses a narrative structure to link an investor (Viking) to questionable related-party transactions involving the target company (Ginkgo).Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
17
The slide uses a 'villain' narrative by comparing Ginkgo's business practices to the failed WeWork IPO strategy.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
18
The slide uses a combination of primary source excerpts and critical commentary to frame the Ferment Fund as a 'slush fund' rather than a legitimate investment vehicle.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
19
The slide uses screenshots of a LinkedIn profile and the Ferment website to build a case of related-party transactions.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
20
The slide uses a Q&A format to present qualitative evidence of a potential conflict of interest or undisclosed related-party transaction.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
21
The slide uses a 'guilt by association' tactic, linking major investors (Cascade, General Atlantic) to individuals with controversial pasts (Michael Larson, Michelle Dipp).Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
22
Uses a comparative narrative to undermine the credibility of the company's leadership and mission statements.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
23
Uses the 'Grow' magazine as evidence of the company's focus on aesthetics over substance.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
24
Uses direct quotes from the company's prospectus to highlight perceived obfuscation.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
25
Uses historical book covers to argue that the company's core technology is not novel.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
26
The slide uses a 'villain' framing by labeling smaller competitors as 'bottom-feeder CRO's'.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
27
The slide uses a 'villain_critique' approach by aggregating negative expert testimony to undermine the company's value proposition.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
28
The slide uses aggressive, activist-style language to frame the company as a 'greater fool SPAC' and 'broken business model'.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
29
The slide uses a combination of financial analysis and qualitative expert/ex-employee testimony to undermine the company's business model.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Villain Critique1 hit
30
The slide uses highlighted quotes from a former senior employee at Ginkgo to substantiate the 'Intrexon 2.0' thesis.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
31
Uses a combination of a chart from the company's own deck and a direct quote from a former employee to undermine the company's narrative.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
32
Uses expert testimony to draw parallels between two companies to frame a short thesis.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
33
Uses yellow highlighting to emphasize key negative phrases within quotes.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
34
The slide uses a Q&A format to present expert testimony.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
35
Ginkgo Bioworks (DNA)Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
36
The slide uses a visual equation (Foundry + Downstream Value) to explain the business model.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
37
Uses yellow highlighting to draw attention to specific clauses in the prospectus text.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
38
The slide uses yellow highlighting to draw attention to specific financial flows in the quoted text.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
39
The slide uses strong, accusatory language ('shell game', 'shocking') to frame the financial data as evidence of deceptive accounting practices.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
40
The slide uses a table to demonstrate the high concentration of deferred revenue from specific related entities.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
41
Uses a direct SEC filing excerpt to substantiate the claim of circular capital flow.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
42
The slide uses a 'callout' box to highlight the suspicious nature of the Synlogic transaction, followed by a primary source excerpt.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit
43
The slide uses a 'modus operandi' argument to suggest a pattern of circular financing between Ginkgo and its related parties.Ginkgo Bioworks (DNA) · Scorpion Capital
Activist deck Short seller Beat · Expose Contradiction1 hit